Literature DB >> 2032418

How malignant is malignant? A brief review of the microscopic assessment of human neoplasms, and the prediction of whether they will metastasize and kill.

I Carr1, N Pettigrew.   

Abstract

This review examines ways in which histopathologists can attempt to predict the degree of malignancy from the microscopic examination of surgically removed samples of human neoplasms. These include mitotic counts, measurement of DNA content, analysis of DNA turnover, measurement of proliferation antigens, measurement of nucleolar organizing areas, counting nucleoli, morphometry of nuclei, identification of genetic change, measurement of lysis of basement membrane, and measurement of invasion in vitro. The latter two are not currently of practical value. Of the rest none is uniformly capable of predicting the degree of malignancy of a human neoplasm. After further refinement and control measurement of several such parameters may however contribute more to the prediction of malignancy than present subjective assessments.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2032418     DOI: 10.1007/bf01756384

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  81 in total

1.  Biological grading of breast cancer using antibodies to proliferating cells and other markers.

Authors:  S S Bacus; R Goldschmidt; D Chin; G Moran; D Weinberg; J W Bacus
Journal:  Am J Pathol       Date:  1989-11       Impact factor: 4.307

2.  Diagnostic value of DNA flow cytometry combined with fine needle aspiration biopsy in lymphomas.

Authors:  H Joensuu; P J Klemi; E Eerola
Journal:  J Pathol       Date:  1988-03       Impact factor: 7.996

3.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

4.  Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer.

Authors:  M P Gallee; E Visser-de Jong; F J ten Kate; F H Schroeder; T H Van der Kwast
Journal:  J Urol       Date:  1989-11       Impact factor: 7.450

5.  In situ demonstration of tissue proliferative activity using anti-bromo-deoxyuridine monoclonal antibody.

Authors:  S Veronese; M Gambacorta; B Falini
Journal:  J Clin Pathol       Date:  1989-08       Impact factor: 3.411

6.  Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.

Authors:  H Tsuda; S Hirohashi; Y Shimosato; T Hirota; S Tsugane; H Yamamoto; N Miyajima; K Toyoshima; T Yamamoto; J Yokota
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

7.  A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness.

Authors:  D A Diamond; S J Berry; H J Jewett; J C Eggleston; D S Coffey
Journal:  J Urol       Date:  1982-10       Impact factor: 7.450

8.  DNA cytofluorometric and nuclear morphometric analyses of lung adenocarcinoma.

Authors:  H Asamura; T Nakajima; K Mukai; M Noguchi; Y Shimosato
Journal:  Cancer       Date:  1989-10-15       Impact factor: 6.860

9.  c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma.

Authors:  M Tavassoli; P Quirke; F Farzaneh; N J Lock; L V Mayne; N Kirkham
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

10.  The prognostic value of morphometrical features and cellular DNA content in cis-platin treated late ovarian cancer patients.

Authors:  J P Baak; N W Schipper; E C Wisse-Brekelmans; T Ceelen; F T Bosman; H van Geuns; J Wils
Journal:  Br J Cancer       Date:  1988-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.